First Patient Dosed in INmune Bio’s Phase1b Trial Testing XPro1595 Anti-inflammatory Compound for Alzheimer’s
| Alzheimer's News Today

INmune Bio has dosed the first patient in its Phase 1b trial (NCT03943264) testing the safety and efficacy of its next-generation anti-inflammatory compound XPro1595 for Alzheimer’s disease (AD). The trial is currently recruiting in different sites across Australia. More information can be found here. Instead of targeting amyloid plaques — or clumps of misfolded proteins […]

Nature Collection on Cell Therapy
| Nature

Cell therapy is becoming established as a modality that has the potential to substantially improve the treatment of a wide range of diseases. This collection features reviews on cell -based therapies for cancer, autoimmune disorders and inherited blood diseases, highlighting the technological advances such as CRISPR-based gene editing and improved viral vectors that have provided […]

How a Pediatric Robot is Making Education Real for Nursing Students

For nursing students at Bunker Hill Community College in Boston, it’s one thing to learn from an instructor or from written material, but it’s far more valuable to interact with a live patient, particularly when it comes to pediatrics, where the patient might not be able to articulate their symptoms as well as an adult […]